|
William K. Oh, M.D., is an American medical oncologist and expert in the management of genitourinary malignancies, including prostate, renal, bladder and testicular cancers. Oh is Chief of the Division of Hematology and Medical Oncology at The Mount Sinai Medical Center in New York City, Associate Director for Clinical Research at Mount Sinai's Tisch Cancer Institute, Professor of Medicine and Urology and the Ezra M. Greenspan, M.D., Professor in Clinical Cancer Therapeutics at The Mount Sinai School of Medicine. In 2009, Oh presented at the American Society of Clinical Oncology the findings of a two-year study which showed that a six-gene molecular diagnostic test, when combined with a PSA test, improved to 90% the accuracy of prostate cancer detection over PSA tests alone. Oh is the author of more than 180 articles and 70 abstracts. He is the editor of 3 books and the author of 18 book chapters. He has been listed in Castle Connolly’s "America’s Top Doctors for Cancer" from 2008 to 2011, "Best Doctors in America" from 2003 to 2011, was listed among Boston Magazine’s "Top Doctors" in 2005 and 2009 and New York Magazine's "Top Doctors" in 2010.〔 ==Biography== Oh earned a B.S. from Yale University in 1987 and his M.D. from New York University School of Medicine in 1992. He completed an internship and a residency at Brigham and Women's Hospital in Boston and a clinical fellowship at the Dana–Farber Cancer Institute. From 1997 to 2009, Oh served on the faculty of Harvard Medical School, where he was named Associate Professor of Medicine in 2007. In 2009, he joined The Mount Sinai Medical Center as the Ezra M. Greenspan Professor in Clinical Cancer Therapeutics and Professor of Medicine and Urology, as well as Chief of the Division of Hematology and Medical Oncology in Mount Sinai's Department of Medicine.〔 Oh is a leading member of the American Society of Clinical Oncology. He has served on multiple editorial boards including the journals The Prostate, Clinical Genitourinary Cancer, the American Journal of Hematology and Oncology and CA – A Cancer Journal for Clinicians. Oh has been the principal investigator on multiple clinical trials of chemotherapy in castration-resistant (CRPC) prostate cancer and for three trials of neoadjuvant chemotherapy in high-risk localized prostate cancer patients. At the Dana–Farber Cancer Institute, from 2000 to 2009, Oh developed and managed a prospective clinical database linked to blood and tissue banks for more than 8,000 prostate cancer patients, with links to blood samples and tissue repositories, for exploration of research and prognostic applications, including: efficacy of various therapies in CRPC, hormonal therapy, testosterone as a marker for cancer outcome, relapse predictions based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「William K. Oh」の詳細全文を読む スポンサード リンク
|